Latest News and Events
Filter by
Selections
January 5, 2024
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
Read MoreJanuary 3, 2024
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
Read MoreDecember 29, 2023
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreDecember 21, 2023
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
Read MoreDecember 21, 2023
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Read MoreNovember 28, 2023